Immunocompromised Patients
GeoVax Vaccine Data Aligns With New IDSA Guidelines for Protecting Immunocompromised Patients
GeoVax's GEO-CM04S1 vaccine demonstrates robust T-cell responses and cross-variant durability in immunocompromised populations, addressing critical gaps identified in new IDSA guidelines that show current COVID-19 vaccines provide only moderate, short-lived protection for vulnerable patients.
New IDSA Guidelines Highlight Critical Need for Tailored COVID-19 Vaccines for Immunocompromised Population
GeoVax's GEO-CM04S1 vaccine addresses the significant protection gap for over 40 million immunocompromised Americans who experience limited effectiveness from current COVID-19 vaccines, as highlighted by new Infectious Diseases Society of America guidelines.
GeoVax Reaffirms Commitment to Vaccine Safety Amid Development of GEO-CM04S1 for Immunocompromised Patients
GeoVax Labs emphasizes its evidence-based approach to vaccine safety and the advancement of GEO-CM04S1, a COVID-19 vaccine designed for vulnerable populations with weakened immune systems who respond poorly to current options.